Amgen Inc. (AMGN) Return on equity 2016–2025
Amgen Inc. (AMGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
89.1%FY2025 · since FY2016: 25.8% → 89.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 89.1% | +19.5 pp |
| FY2024 | 69.6% | -38.2 pp |
| FY2023 | 107.8% | -71.2 pp |
| FY2022 | 179.0% | +91.0 pp |
| FY2021 | 88.0% | +10.8 pp |
| FY2020 | 77.2% | -3.9 pp |
| FY2019 | 81.1% | +13.9 pp |
| FY2018 | 67.2% | +59.3 pp |
| FY2017 | 7.8% | -18.0 pp |
| FY2016 | 25.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AMGN financial trends
AMGN RevenueAMGN Net incomeAMGN Net marginAMGN Gross profitAMGN Gross marginAMGN Operating incomeAMGN Operating marginAMGN Operating cash flowAMGN Free cash flowAMGN Capital expendituresAMGN Stock buybacksAMGN Dividends paidAMGN Total assetsAMGN Total liabilitiesAMGN Shareholders’ equityAMGN overview →